List of Slynd drug patents

Slynd is owned by Exeltis Usa Inc.

Slynd contains Drospirenone.

Slynd has a total of 13 drug patents out of which 0 drug patents have expired.

Slynd was authorised for market use on 23 May, 2019.

Slynd is available in tablet;oral dosage forms.

Slynd can be used as prevention of pregnancy in females of reproductive age.

The generics of Slynd are possible to be released after 28 June, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11351122 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11478487 EXELTIS USA INC NA
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 23, 2022

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 23 May, 2019

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET;ORAL

How can I launch a generic of SLYND before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in